Bivalirudin: A Direct Thrombin Inhibitor for Percutaneous Transluminal Coronary Angioplasty

Pharmacotherapy

Volumn 22, Issue 8, 2002, Pages 1007-1018

  Wiggins, Barbara S ^a   Spinler, Sarah ^b   Wittkowsky, Ann K ^c   Stringer, Kathleen A ^d  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ARGATROBAN; CLOPIDOGREL; DALTEPARIN; EPTIFIBATIDE; FIBRIN; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; STREPTOKINASE; THROMBIN; TICLOPIDINE; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANTICOAGULATION; ARTICLE; BACKACHE; BLEEDING; BLOOD CLOTTING TIME; BRADYCARDIA; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DOSE CALCULATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DYSPEPSIA; FEVER; HEADACHE; HUMAN; HYPOTENSION; INJECTION PAIN; INSOMNIA; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PELVIS PAIN SYNDROME; TRANSLUMINAL CORONARY ANGIOPLASTY; VOMITING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMPARATIVE STUDY; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDIN; HUMAN; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; THROMBIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; HIRUDINS; HUMANS;

EID: 0036021209     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.12.1007.33600     Document Type: Article

References (54)

1. Acute coronary syndromes
2. Redefining medical treatment in the management of unstable angina
3. Direct medical costs of coronary artery disease in the United States
4. ACC/AHA Guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty)
5. Heparin and low molecular weight heparin: Mechanism of action, pharmacokinetics, dosing, monitoring, efficacy and safety
6. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention
7. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
8. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
9. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the bivalirudin angioplasty study
10. Biochemical and molecular aspects of the coagulation cascade
11. Antithrombotic strategies targeting thrombin activities, thrombin receptors, and thrombin generation
12. A player in many parts: The spotlight falls on thrombin's structure
13. Modulation of thrombin and heparin activities by fibrin
14. The hirudins: Antithrombin anticoagulants
15. New antithrombotic agents
16. The mechanism of action of thrombin inhibitors
17. Beyond heparin and aspirin: New treatments for unstable angina and non-Q-wave myocardial infarction
18. The use of bivalirudin in patients with renal impairment
19. Hirulog: A direct thrombin inhibitor for management of acute coronary syndromes
20. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention
21. Bivalirudin: A new generation antithrombotic drug
22. The influence of dose, gender and kidney function on bivalirudin pharmacokinetics and pharmacodynamics in patients undergoing percutaneous transluminal angioplasty
23. A pharmacokinetic and pharmacodynamic study of BG8967 in subjects with renal insufficiency. Study C93-313
24. A new rapid ecarin clotting time assay but not activated clotting time strongly correlates with bivalirudin concentration: A percutaneous coronary intervention study
25. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty
26. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable angina or postinfarction angina
27. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina
28. A second look at bivalirudin
29. Evolution of improved antithrombotic and antiplatelet agents: Genesis of the comparison of abciximab complications with Hirulog (and back-up abciximab) events trial (CACHET)
30. Antithrombin, antiplatelet therapy or both during PCI: A preliminary, randomized trial
31. The REPLACE 1 trial: A pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade
32. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial
33. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
34. Pharmacodynamic profile of the direct thrombin inhibitor antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide
35. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention
36. Unstable angina/myocardial infarction: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction
37. Coronary heart disease/myocardial infarction: Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction
38. Randomized, double-blind comparison of Hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)
39. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
40. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
41. Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/early reperfusion occlusion (HERO 2) study
42. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial
43. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)
44. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non- ST-elevation myocardial infarction: Observations from the TIMI 8 trial
45. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty
46. Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized controlled trials
47. Hemorrhagic complications in association with percutaneous coronary intervention: Can the risk be attenuated?
48. Clinical outcomes of bivalirudin for ischemic heart disease
49. Current trends in the development of anticoagulant and antithrombotic drugs
50. Cost analysis of bivalirudin in percutaneous coronary intervention